Clinical trials: Leukemia, Chronic Lymphatic
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This phase II trial tests how well tacabrutideg and sonrotoclax, with response-guided addition of obinutuzumab, works in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT07887061
- Testing
- Tacabrutideg, Sonrotoclax, Obinutuzumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
This trial will assess the tolerability and safety of AFX-2 over a range of five dose levels in adults with low-, intermediate- or high-risk Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01456182
- Testing
- AFX-2
- Where
- 3 sites in United States
- Sponsor
- Afexa Life Sciences Inc
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease
- Trial name
- NCT06815003
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
This study explores the potential to improve the quality of response obtained after induction treatment in Chronic Lymphocytic Leukemia (CLL), by giving a short and intense consolidation schema using high-dose rituximab.
- Trial name
- HYDRIC (NCT01625741)
- Testing
- Rituximab
- Where
- 15 sites in Belgium
- Volunteers
- 6 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Chronic Lymphocytic Leukemia
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
The purpose of this research study is to see if Dasatinib is effective and safe to give to people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the drug on LYN kinase activity in blood and bone…
- Trial name
- NCT00438854
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Chronic Lymphocytic Leukemia
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy.
- Trial name
- NCT03128879
- Testing
- Ibrutinib, Venetoclax, Acalabrutinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Non Hodgkin Lymphoma, Hodgkin Lymphoma
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with…
- Conditions
- Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT02507479
- Testing
- Thiotepa
- Where
- 2 sites in Israel
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Leukemia
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Vaccines may make the body build an immune response to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
- Trial name
- NCT00004052
- Testing
- QS21, bcr-abl peptide vaccine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies.
- Conditions
- Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01696461
- Testing
- Plerixafor
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia.
- Trial name
- NCT00003694
- Testing
- omacetaxine mepesuccinate, cytarabine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have recurrent…
- Trial name
- NCT00005829
- Testing
- gemcitabine hydrochloride
- Volunteers
- 22 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
- Trial name
- NCT00038831
- Testing
- Mylotarg, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphocytic Leukemia, Chronic
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01998880
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Acute Disease, Myelodysplastic Syndromes
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).
- Conditions
- Acute Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Myeloproliferative Disorders
- Trial name
- NCT00186342
- Testing
- ablative allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were…
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation
- Trial name
- NCT02553941
- Testing
- Azacitidine, Ibrutinib
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Brian Jonas
Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
This phase II trial is studying imatinib mesylate to see how well it works in treating patients with chronic myelogenous leukemia.
- Conditions
- Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia
- Trial name
- NCT00030394
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands
The study design is a prospective, non-interventional, observational single arm study. A minimum of 150 patients will be recruited from approximately 30 haematology/oncology sites in the Netherlands.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- OCEAN (NCT02891551)
- Volunteers
- 209 people
- Sponsor
- Celgene
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin and bortezomib in treating patients with relapsed or refractory hematologic cancer.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00103272
- Testing
- tanespimycin, bortezomib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
RATIONALE: Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells.
- Trial name
- NCT00437086
- Testing
- PS-341
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic